EUVIMEDEUVIMED entdecken
Crossref

Optimizing Cervical Cancer Screening by Age at Vaccination for Human Papillomavirus: Health and Resource Implications

Kine Pedersen iD, Jacopo Di Silvestre iD, Stephen Sy iD, Allison Portnoy iD, Philip E Castle iD, Jane J Kim, Emily A Burger iD

Annals of Internal Medicine · 2026

DOI: 10.7326/annals-25-03192 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Internal Medicine, 2026. Verfasst von Kine Pedersen und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Oslo, Department of Health Management and Health Economics, Oslo, Norway (K.P., J.Di S.). Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Vaccines, Papillomavirus Infections, Early Detection of Cancer. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Widespread vaccination for human papillomavirus (HPV) alters the landscape of cervical cancer (CC) risk, requiring adaptations to the CC screening program. OBJECTIVE: To assess the cost-effectiveness and harm-benefit tradeoffs of adapting CC screening strategies on the basis of age at HPV vaccination. DESIGN: Individual-based mathematical modeling study. DATA SOURCES: Published data. TARGET POPULATION: Hypothetical cohorts of women vaccinated in 7 different age groups (12, 13 to 15, 16 to 18, 19 to 21, 22 to 24, 25 to 27, and 28 to 30 years) with either bivalent or nonavalent vaccines in Norway. TIME HORIZON: Lifetime. PERSPECTIVE: Extended health care sector (that is, including patient time and travel costs). INTERVENTION: HPV-based screening strategies that varied screening start age, interval, and number of lifetime screening tests. OUTCOME MEASURES: Incremental cost-effectiveness ratios, defined as the additional cost per quality-adjusted life-year (QALY) gained. "Preferred" (that is, cost-effective) screening for each age group was identified using a cost-effectiveness threshold of $55 000 per QALY. Harm-benefit tradeoffs were quantified as the ratio of colposcopy referrals to CC cases averted. RESULTS OF BASE-CASE ANALYSIS: For all vaccination age groups and both vaccines, less frequent screening with longer intervals between screening than the 5-year interval currently recommended was consistently preferred at the threshold of $55 000 per QALY, but the preferred strategy varied by age at vaccination. For women vaccinated between ages 12 and 24 years, preferred strategies involved screening every 15 to 25 years, resulting in screening 2 to 3 times per lifetime. RESULTS OF SENSITIVITY ANALYSIS: Less frequent screening remained a preferred strategy under imperfect screening adherence and in scenarios that excluded bivalent vaccine cross-protection. LIMITATION: The analysis did not address screening for unvaccinated women, who may benefit from herd immunity. CONCLUSION: A high-value screening program likely involves less frequent screening for women who were vaccinated against HPV by age 30 years. Strategies could be tailored on the basis of age at vaccination and type of HPV vaccine. PRIMARY FUNDING SOURCE: Norwegian Cancer Society and National Cancer Institute.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsPapillomavirus VaccinesPapillomavirus InfectionsEarly Detection of CancerMass ScreeningHumansFemaleCost-Benefit AnalysisAdolescentAdultAge FactorsQuality-Adjusted Life YearsCost-Effectiveness AnalysisYoung AdultChildColposcopyNorwayModels, TheoreticalHuman Papillomavirus Viruses

Substanzen

Papillomavirus Vaccines

Autor:innen und Institutionen

  • University of Oslo, Department of Health Management and Health Economics, Oslo, Norway (K.P., J.Di S.).
  • Harvard T.H. Chan School of Public Health, Center for Health Decision Science, Boston, Massachusetts (S.S., J.J.K.).
  • Harvard T.H. Chan School of Public Health, Center for Health Decision Science, and Boston University School of Public Health, Department of Global Health, Boston, Massachusetts (A.P.).
  • National Cancer Institute, Divisions of Cancer Prevention and Cancer Epidemiology and Genetics, Rockville, Maryland (P.E.C.).
  • University of Oslo, Department of Health Management and Health Economics, Oslo, Norway, and Harvard T.H. Chan School of Public Health, Center for Health Decision Science, Boston, Massachusetts (E.A.B.).

ORCID-Profile: Kine Pedersen, Jacopo Di Silvestre, Stephen Sy, Allison Portnoy, Philip E Castle, Emily A Burger

Zitieren

APA

Pedersen, K., Di Silvestre, J., Sy, S., Portnoy, A., Castle, P. E., Kim, J. J., & Burger, E. A. (2026). Optimizing Cervical Cancer Screening by Age at Vaccination for Human Papillomavirus: Health and Resource Implications. Annals of Internal Medicine. https://doi.org/10.7326/annals-25-03192

Vancouver

Pedersen K, Di Silvestre J, Sy S, Portnoy A, Castle PE, Kim JJ, et al. Optimizing Cervical Cancer Screening by Age at Vaccination for Human Papillomavirus: Health and Resource Implications. Annals of Internal Medicine. 2026. doi:10.7326/annals-25-03192

BibTeX
@article{Pedersen2026,
  author = {Pedersen, Kine and Di Silvestre, Jacopo and Sy, Stephen and Portnoy, Allison and Castle, Philip E and Kim, Jane J and Burger, Emily A},
  title = {Optimizing Cervical Cancer Screening by Age at Vaccination for Human Papillomavirus: Health and Resource Implications},
  journal = {Annals of Internal Medicine},
  year = {2026},
  doi = {10.7326/annals-25-03192}
}
Kostenlos starten →